Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes

Jastreboff A.M. et al.

Tirzepatide's coming-out party. At the 15 mg dose, participants lost a mean 22.5% of body weight over 72 weeks across 2,539 adults without diabetes — numbers that approach bariatric-surgery territory and reset every expectation for pharmacotherapy.

Wilding J.P.H. et al.

The trial that turned semaglutide into a household word. 14.9% mean body-weight reduction at 68 weeks vs. 2.4% on placebo across 1,961 adults — the result that opened the floodgates for the entire GLP-1 wave.

Aronne L.J. et al.

The head-to-head everyone was waiting for. 751 adults over 72 weeks: 20.2% weight loss with tirzepatide vs. 13.7% with semaglutide at max tolerated doses — a 6.5-point gap that's clinically meaningful but smaller than the marketing suggests. Both drugs work; tirzepatide works more.

Sanyal A.J. et al.

ESSENCE Part 1 hit both primary endpoints at 72 weeks: MASH resolution without fibrosis worsening, and fibrosis improvement without MASH worsening. This is what got semaglutide an FDA MASH indication and made GLP-1s a liver story too.